新易盛(300502.SZ):目前已成功推出業界最新的基於單波200G光器件的800G/1.6T光模塊產品
格隆匯5月10日丨新易盛(300502.SZ)於2024年5月9日召開業績説明會,就“光模塊行業產品更新迭代速度很快,請問公司在新產品端的進展情況如何?”,公司回覆稱,公司一向重視行業新技術、新產品的研究,目前已成功推出業界最新的基於單波200G光器件的800G/1.6T光模塊產品,高速光模塊產品組合涵蓋VCSEL/EML、硅光、薄膜磷酸鋰等技術解決方案;推出400G和800GZR/ZR+相干光模塊產品、以及基於LPO方案的400G/800G光模塊。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.